The melanoma differentiation-associated gene-7 (MDA-7) protein, also known as interleukin 24 , is a novel candidate of tumor suppressor that has been found to experimentally induce apoptosis and growth inhibition in a variety of human malignant cells. However, there have been few studies about its role in lung adenocarcinoma. Even at the same stage and with similar pathologic characteristics, lung adenocarcinomas with a diameter of 3 cm or less can have a variable prognosis depending on their biologic characteristics. The purpose of this study is to define the relationship between MDA-7/IL-24 expression and the progression of small-sized lung adenocarcinomas. Materials and Methods: We performed immunohistochemical detection of MDA-7/ IL-24 in forty-seven tissue samples from primary lung adenocarcinomas of ≤3 cm in diameter by using tissue microarray. Results: MDA-7/IL-24 immunoreactivity was observed in 20 (42.6%) of the 47 adenocarcinoma cases. MDA-7/IL-24 expression was positive in 66.7% of the adenocarcinomas ≤2 cm, and in 31.3% of the adenocarcinomas ＞2 cm or ≤3 cm in diameter. A statistically significant association was found between MDA-7/IL-24 expression and tumor size (p=0.03). Although this difference did not reach statistical significance, tumors with a negative MDA-7/IL-24 expression tended to more frequently show lymph node metastasis (p=0.07). There were no significant associations for other clinicopathologic characteristics. Conclusion: These results suggest the possible involvement of MDA-7/IL-24 in the growth and progression of small-sized lung adenocarcinoma. MDA-7/IL-24 immunoreactivity could be used to identify a subset of adenocarcinomas of the lung of 3 cm or less in diameter that have different biologic behavior. (J Lung Cancer 2012;11(2): 71 76)
INTRODUCTION
Lung cancer is a major cause of cancer deaths. Among the histologic types of lung cancer, adenocarcinoma is becoming the most common in a majority of countries including Korea (1) . Many types of small adenocarcinomas can now be detected as a result of advances in diagnostic methods. Despite their small size, however, some of these will already be advanced tumors at the time of diagnosis, or they may develop distant metastasis after complete surgical resection (2) . Furthermore, lung adenocarcinomas are histologically heterogeneous with their characteristic patterns being lepidic, acinar, papillary, micropapillary, and solid (3) . Given the histological and biological heterogeneity of adenocarcinomas, it is difficult to predict patient outcomes. Although several well-known biological markers have been reported, it is important to detect further biological markers of this tumor so as to develop appropriate treatment strategies and reliable estimates of the probability of patient survival.
Melanoma differentiation associated gene-7 (MDA-7), also known as interleukin 24 (IL-24), is a novel candidate of tumor 72 J Lung Cancer 2012;11 (2) :71-76 suppressor associated with differentiation, growth and apoptosis (4) . MDA-7/IL-24 was discovered using a subtraction hybridization approach by exposing melanoma cells to terminal differentiation agents including interferon-ß and mezerein (4, 5) .
Ectopic transfer of MDA-7/IL-24 has been shown in vitro to suppress growth and induce apoptosis in a variety of human tumor cell lines, but similar effects have not been elicited in normal cells (6, 7) . MDA-7/IL-24 is believed to be associated with the induction of key molecules, thereby altering the balance between the pro-and anti-apoptotic proteins that mediate growth inhibition and apoptosis in several tumor types (8) . As such, MDA-7/IL-24 seems to function as a novel tumor suppressor, and there is interest in the potential of MDA-7/IL-24 gene transfer as cancer therapy. However, only one study has documented the clinical significance of MDA-7/IL-24 expression in non-small cell lung cancer (NSCLC), with positive MDA-7/ IL-24 expression being found to be a significant factor for predicting favorable prognosis in adenocarcinoma (9) .
Taking into account the importance of MDA-7/IL-24 in lung adenocarcinoma found in this earlier study, we performed immunohistochemical detection of MDA-7/IL-24 protein in lung adenocarcinoma tissue samples that had a maximal tumor diameter of 3 cm or less by using tissue microarray (TMA).
The purpose of the current study is to define the relationship between MDA-7/IL-24 expression and the progression of smallsized lung adenocarcinoma. This is the first study to determine the clinicopathological role of MDA-7/IL-24 expression in Korean lung adenocarcinoma patients. 
MATERIALS AND METHODS

1) Patients and tissue samples
3) Immunohistochemistry
Immunohistochemical staining for MDA-7/IL-24 was performed on the TMA slides by using the avidin-biotin-peroxidase complex method. Deparaffinization of all the sections was performed through a series of xylene baths, and rehydration was performed with a series of graded alcohol solutions. To enhance the immunoreactivity, microwave antigen retrieval was other scores were considered to be negative.
5) Statistical analysis
Associations between MDA-7/IL-24 expression and the clinicopathologic characteristics of the tumors were analyzed using the χ 2 test or Fisher's exact test. A p-value of less than 0.05 was considered statistically significant. All statistical tests were performed with SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS
1) Clinicopathologic characteristics
2) Immunohistochemical findings
All the tumor cores demonstrated similar staining characteristics. Six cases had only two cores with adequate tissue to carry out evaluation. The staining patterns of the TMA cores showed results that were concordant with those for the five full 
DISCUSSION AND CONCLUSION
In the present study, we have shown the prevalence of MDA-7/IL-24 immunoreactivity in the adenocarcinomas of the lung that were 3 cm or less in diameter, and we found a signi- Although its physiological role is poorly understood, multiple anticancer mechanisms of MDA-7/IL-24 have been reported, including cancer-specific apoptosis induction, cell cycle regulation, an ability to inhibit angiogenesis, potent bystander antitumor activity, and a capacity to enhance the sensitivity of tumor cells to radiation and chemotherapy (13, 14) . 
